[go: up one dir, main page]

BR112015022582A2 - molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo - Google Patents

molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo

Info

Publication number
BR112015022582A2
BR112015022582A2 BR112015022582A BR112015022582A BR112015022582A2 BR 112015022582 A2 BR112015022582 A2 BR 112015022582A2 BR 112015022582 A BR112015022582 A BR 112015022582A BR 112015022582 A BR112015022582 A BR 112015022582A BR 112015022582 A2 BR112015022582 A2 BR 112015022582A2
Authority
BR
Brazil
Prior art keywords
fmdv
plasmid
methods
nucleic acid
individual
Prior art date
Application number
BR112015022582A
Other languages
English (en)
Other versions
BR112015022582B1 (pt
Inventor
Weiner David
Yan Jian
Muthumani Karuppiah
Y Sardesai Niranjan
Original Assignee
The Trustees Of The Univ Of Pennsylvania E Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The Univ Of Pennsylvania E Inovio Pharmaceuticals Inc filed Critical The Trustees Of The Univ Of Pennsylvania E Inovio Pharmaceuticals Inc
Publication of BR112015022582A2 publication Critical patent/BR112015022582A2/pt
Publication of BR112015022582B1 publication Critical patent/BR112015022582B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1 / 1 resumo “molã‰cula de ãcido nucleico, plasmãdeo, vacina, e, mã‰todos para gerar uma resposta imune contra fmdv em um indivãduo, para prevenir uma infecã‡ãƒo por fmdv em um indivãduo e para tratar um indivãduo que foi infectado com fmdv” a presente invenã§ã£o se refere a proteã­nas imunogãªnicas do vã­rus da doenã§a da febre aftosa (fmdv) de consenso sintã©ticas e molã©cula de ã¡cido nucleico que codifica essas proteã­nas, vacinas contra fmdv, mã©todos para induzir respostas imunes contra fmvd, mã©todos para distinguir entre indivã­duos infectados com fmdv versus aqueles vacinados contra fmdv, e mã©todos de imunizar indivã­duos de forma profilã¡tica e/ou terapãªutica contra fmdv.
BR112015022582-9A 2013-03-15 2014-03-17 Molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo BR112015022582B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361802225P 2013-03-15 2013-03-15
US201361794197P 2013-03-15 2013-03-15
US61/802,225 2013-03-15
US61/794,197 2013-03-15
PCT/US2014/030809 WO2014145951A2 (en) 2013-03-15 2014-03-17 Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom

Publications (2)

Publication Number Publication Date
BR112015022582A2 true BR112015022582A2 (pt) 2017-10-24
BR112015022582B1 BR112015022582B1 (pt) 2024-01-09

Family

ID=51538575

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022582-9A BR112015022582B1 (pt) 2013-03-15 2014-03-17 Molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo

Country Status (11)

Country Link
US (1) US9993545B2 (pt)
EP (2) EP3756683A1 (pt)
JP (4) JP6817062B2 (pt)
KR (3) KR20210088754A (pt)
CN (2) CN105338998B (pt)
AU (1) AU2014232363B2 (pt)
BR (1) BR112015022582B1 (pt)
CA (1) CA2895806C (pt)
ES (1) ES2817903T3 (pt)
MX (2) MX377803B (pt)
WO (1) WO2014145951A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993545B2 (en) * 2013-03-15 2018-06-12 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
EP3452068A4 (en) * 2016-05-05 2020-01-22 The Trustees of The University of Pennsylvania FILOVIRUS CONSENSUS ANTIGENS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING THE SAME
US10385319B2 (en) * 2016-09-08 2019-08-20 The Governement of the United States of America, as represented by the Secretary of Homeland Security Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof
WO2018098220A1 (en) * 2016-11-22 2018-05-31 The Wistar Institute Of Anatomy And Biology Foot and mouth disease virus serotype o (fmdv-o) vaccine
WO2019132569A1 (ko) * 2017-12-29 2019-07-04 (주)플럼라인생명과학 구제역 바이러스 a형 백신 조성물
KR102165358B1 (ko) * 2017-12-29 2020-10-14 (주)플럼라인생명과학 구제역 바이러스 a형 백신 조성물
EP4076518A4 (en) * 2019-12-19 2024-04-10 The Wistar Institute of Anatomy and Biology VACCINE AGAINST AFRICAN SWINE FEVER VIRUS AND METHOD OF USE THEREOF
WO2024112115A1 (ko) * 2022-11-23 2024-05-30 주식회사 옵티팜 구제역 바이러스 유사 입자 또는 나노입자 생산을 위한 재조합 발현 벡터 및 이를 이용한 백신 조성물

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21579A (en) 1858-09-21 Rotary valve fob steam-engines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
AU625584B2 (en) 1989-03-08 1992-07-16 Health Research Inc. Recombinant poxvirus host selection system
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
ES2090129T3 (es) 1989-03-31 1996-10-16 Univ Washington Vacunas que contienen microorganismos tipo phop avirulentos.
EP0431668B1 (en) 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
IL108449A (en) 1993-01-26 2011-09-27 Weiner David B Assemblies and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
NZ267838A (en) 1993-06-07 1997-12-19 Genentech Inc Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
KR100427786B1 (ko) 1997-04-03 2004-04-30 일렉트로우펙트 에이에스 약물과 핵산의 골격 근육 내 주입 장치 및 방법
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
KR20010020571A (ko) 1997-06-30 2001-03-15 자끄 사비나 횡문근중으로 개선된 핵산 전달방법 및 이를 위한콤비네이션
US6107021A (en) 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
AU770092B2 (en) 1998-07-13 2004-02-12 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
NZ514104A (en) 1999-03-18 2001-09-28 Exiqon As Detection of mutations in genes by specific LNA primers
FR2810888B1 (fr) * 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
TWI290174B (en) 2002-11-04 2007-11-21 Advisys Inc Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
US7517520B2 (en) 2003-03-26 2009-04-14 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
EP2666858A1 (en) 2003-04-17 2013-11-27 Alnylam Pharmaceuticals Inc. Modified iRNA agents
CA2567324C (en) 2003-05-30 2012-01-03 Advisys, Inc. Devices and methods for biomaterial production
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
US20050182005A1 (en) 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
PL1773387T3 (pl) 2004-06-25 2013-10-31 Merial Inc Rekombinanty wirusa ospy ptasiej wyrażające geny wirusa pryszczycy
CN1737144A (zh) 2004-08-18 2006-02-22 金宁一 口蹄疫复合多表位二价核酸疫苗的构建
EP1632247A1 (en) * 2004-09-03 2006-03-08 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding FMDV proteins capable of associating into a virus-like particle
WO2006063445A1 (en) 2004-12-14 2006-06-22 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Recombinant foot and mouth disease vaccine
CN100582122C (zh) 2006-05-12 2010-01-20 北京宝麦德生物医药科技有限责任公司 O型口蹄疫病毒多表位粘膜免疫疫苗及其应用
CN101121938B (zh) 2007-03-23 2010-10-06 中国农业科学院兰州兽医研究所 一种口蹄疫抗原的制备方法
CA2705461A1 (en) 2007-11-12 2009-06-11 The Trustees Of The University Of Pennsylvania Vaccines against multiple subtypes of influenza virus
CN101270155B (zh) 2008-05-06 2011-04-27 中国农业科学院兰州兽医研究所 通过耐酸性改造在昆虫中组装口蹄疫病毒空衣壳的方法
CA2777705C (en) 2009-11-02 2019-03-12 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
EP3093025B1 (en) * 2010-03-12 2018-08-01 Merial Inc. Bluetongue virus recombinant vaccines and uses thereof
US8765141B2 (en) * 2010-07-01 2014-07-01 The United States Of America, As Represented By The Secretary Of Agriculture Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host
GB201014965D0 (en) * 2010-09-08 2010-10-20 Animal Health Inst Vaccine
US20140236070A1 (en) * 2011-07-29 2014-08-21 Kate Broderick Linear expression cassettes and uses thereof
US9993545B2 (en) * 2013-03-15 2018-06-12 The Trustees Of The University Of Pennsylvania Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom

Also Published As

Publication number Publication date
US9993545B2 (en) 2018-06-12
JP2023063383A (ja) 2023-05-09
MX2020012913A (es) 2021-02-26
JP2019141069A (ja) 2019-08-29
BR112015022582B1 (pt) 2024-01-09
CN105338998A (zh) 2016-02-17
JP7245282B2 (ja) 2023-03-23
MX2015011487A (es) 2016-02-03
JP6947773B2 (ja) 2021-10-13
EP3756683A1 (en) 2020-12-30
US20160045589A1 (en) 2016-02-18
CN114045295A (zh) 2022-02-15
KR20160002757A (ko) 2016-01-08
WO2014145951A3 (en) 2014-12-18
AU2014232363A8 (en) 2015-08-06
CA2895806A1 (en) 2014-09-18
ES2817903T3 (es) 2021-04-08
CA2895806C (en) 2023-02-21
EP2968519A4 (en) 2016-03-30
KR20210088754A (ko) 2021-07-14
KR20230062666A (ko) 2023-05-09
EP2968519A2 (en) 2016-01-20
WO2014145951A2 (en) 2014-09-18
CN105338998B (zh) 2021-12-14
EP2968519B1 (en) 2020-05-06
MX377803B (es) 2025-03-11
AU2014232363B2 (en) 2017-03-02
JP6817062B2 (ja) 2021-01-20
JP2021126118A (ja) 2021-09-02
JP2016515820A (ja) 2016-06-02
KR102276405B1 (ko) 2021-07-12
AU2014232363A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
WO2017191258A8 (en) Influenza mrna vaccines
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
BR112015005987A2 (pt) vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
CL2016002794A1 (es) Vacuna de péptido que comprende un péptido ras mutante y un agente quimioterapéutico
BR112016015422A2 (pt) formulações de vacina de frasco único
BRPI0923448A2 (pt) vírus influenza rearranjado, composição antigênica de vírus influenza rearranjado, vacina, e, métodos para provocar uma resposta imune a pelo menos uma cepa pandêmica de vírus influenza em um indivíduo, para prevenir infecção de um indivíduo por um vírus influenza, e para preparar uma vacina.
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
PE20151588A1 (es) Vacuna contra el virus del dengue
BR112016002354A2 (pt) composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit
CL2017003224A1 (es) Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante
BR112018015893A2 (pt) vacinas de câncer e métodos de tratamento usando as mesmas
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
BR112017002440A2 (pt) vírus da diarreia epizoótica porcina mutante para utilização em uma vacina
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
BR112014023414A2 (pt) vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos
MX386606B (es) El uso de una vacuna para la prevención de diarrea epidémica porcina.
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
MX390304B (es) Proceso para preparar una vacuna tetravalente atenuada contra el dengue.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023014258-6 PROTOCOLO 870230062188 EM 14/07/2023 17:21.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2014, OBSERVADAS AS CONDICOES LEGAIS